Positive results for CAPTIVATE: ibrutinib and venetoclax for CLL

Positive results for CAPTIVATE: ibrutinib and venetoclax for CLL

User Photo
VJHemOnc

2 years
113 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Paolo Ghia, MD, of the Università Vita-Salute San Raffaele, Milan, presented preliminary data from the Phase II CAPTIVATE trial (NCT02910583) at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. This trial combined ibrutinib and venetoclax in the frontline treatment of chronic lymphocytic leukemia (CLL), with the aim of yielding deeper responses than current standard therapies. Dr Ghia discusses the promising data from the trial, with 86% of patients reaching MRD negativity, and the treatment being as well tolerated as standard monotherapies.
Up Next Autoplay